NetApp Teams with VMware, AWS to Help Customers Modernize and Scale Enterprise Workloads on the Cloud
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, in collaboration with VMware, Inc. and Amazon Web Services (AWS), today announced the general availability of Amazon FSx for NetApp ONTAP with VMware Cloud on AWS, the first and only native AWS cloud storage service certified and supported as a supplemental datastore for VMware Cloud on AWS.
With this new datastore solution, enterprises can quickly, easily and cost-effectively move their enterprise, data-demanding workloads to VMware Cloud on AWS. This allows organizations to scale cloud storage independent of cloud compute to optimize costs, deploy new modern applications with the speed and scalability of the cloud, and maximize the value of their existing IT investments. Additionally, organizations can gain access to the rich data management, protection, and efficiency benefits of ONTAP utilized by nearly twenty thousand VMware customers running on-premises today.
“Our strong relationship, deep integration and joint innovation with both VMware and AWS hits another milestone, which helps make it easier for organizations to efficiently move enterprise workloads to the cloud,” said Phil Brotherton, Vice President, Solutions & Alliances at NetApp. “VMware customers running on NetApp or non-NetApp storage onpremises can now access the enterprise-class public cloud storage services and features of ONTAP, all running on AWS, as the first certified and supported supplemental datastore to VMware Cloud on AWS.”
“The majority of enterprises today run workloads on a VMware platform. Whether that is on premises or in VMware Cloud on AWS, they want to be able to leverage consistency in operations and architecture,” said Narayan Bharadwaj, Vice President, Cloud Solutions at VMware. “AWS, NetApp and VMware are giving customers the flexibility to buy and configure cloud storage independent of compute to meet the needs of a wide variety of enterprise applications. Our co-innovation will enable customers moving enterprise workloads to the cloud to cost-optimize and better scale their environments.”
New benefits from this certified and supported offering include improved:
- Speed: Migrate data-demanding on-premises vSphere-based workloads with NetApp or non-NetApp storage to VMware Cloud on AWS with reduced complexity – leveraging consistent VMware-to-VMware migration for workloads combined with the speed, performance and simplicity of ONTAP via Amazon FSx for NetApp ONTAP.
- Cost Control: Scale VMware Cloud compute independent of cloud storage to optimize cost at scale for demanding workloads combined with the rich data efficiency features of ONTAP to control cost at scale, including dedupe, compression, compaction, and thin provisioning.
- Efficiency: Leverage existing VMware-centric resource investments including people, processes and technologies from on-premises and on the cloud for consistency of operations.
In addition, partners of NetApp, VMware and AWS can benefit from this innovation to expand their current offerings around VMware Cloud in multiple ways:
- Unlock new business for hybrid and cloud-native workloads through breaking down cost barriers to migrating enterprise workloads through right-sizing cloud compute and cloud storage.
- Expand existing cloud services helping customers plan, design, deploy and optimize enterprise hybrid and cloud-native solutions for data-demanding workloads.
- Reduce risk for their clients through integrated and supported cloud solutions from NetApp and VMware to help customers migrate, extend or protect enterprise workloads to the cloud with confidence.
“As a leading multi-brand provider of full stack IT solutions, our customers rely on us to deliver solutions and services to help them manage their most data-demanding workloads,” said Troy Brick-Margelofsky, Digital Infrastructure Team Lead at CDW. “With Amazon FSx for NetApp ONTAP as a certified and supported datastore for VMware Cloud, we can now help customers move workloads on to the cloud quickly and efficiently, saving them time, money, and resources with the added benefit of integration with the complete NetApp portfolio.”
Amazon FSx for NetApp ONTAP provides fully managed shared storage on AWS with the popular data access and management capabilities of ONTAP. The solution allows organizations to easily migrate applications and run them on AWS, with ONTAP’s enterprise-grade storage workflows and data management capabilities, regardless of their on-premises storage provider.
Amazon FSx for NetApp ONTAP supplemental datastore for VMware Cloud on AWS is available today.
Additional Resources
- VMware Announcement
- Blog: Announcing VMware Cloud on AWS integration with Amazon FSx for NetApp ONTAP
- Blog: The Power of Partnerships: Taking Multi-Cloud Mainstream
- Amazon FSx for NetApp ONTAP
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
VMware and vSphere are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005373/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom